NBY  Novabay Pharmaceuticals Inc.

Exchange

AMEX

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

38.2M

Vuru Grade

30.66/100

Current Price

$0.75
+0.0026 (+0.35%)

Stability Price

$0.62
Overvalued by 17.00%

Company Metrics

  • 0 P/E
  • 18.85 P/S
  • 4.12 P/B
  • -0.335 EPS
  • -2,345.19% Cash ROIC
  • 3.60 Cash Ratio
  • 0.00 / N/A % Dividend
  • 333,848.00 Avg. Vol.
  • 38.18M Shares
  • 38.2M Market Cap.

Company Description

NovaBay Pharmaceuticals Inc., a clinical stage biotechnology company, engages in developing proprietary and patented topical Aganocide compounds for the treatment and prevention of various infections without causing bacterial resistance. Its Aganocide compounds are synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white bloo...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

NovaBay Pharmaceuticals Creates Optometry Advisory Board
MarketWatch - Sep 18, 2014
EMERYVILLE, Calif., Sep 18, 2014 (BUSINESS WIRE) -- NovaBay® Pharmaceuticals, Inc. (nyse mkt:NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products,announced today that it ...
NovaBay off big after trial fails (NBY)
Seeking Alpha (registration) - Aug 20, 2014
The global study enrolled patients with adenoviral conjunctivitis in the U.S., India, Sri Lanka and Brazil. The endpoints were: measured clearing of bulbar conjunctival injection (red eye); eradication of adenovirus from tear film; spread of infection ...
NovaBay Pharmaceuticals to Present at Rodman & Renshaw 16th Annual ...
MarketWatch - Sep 5, 2014
EMERYVILLE, Calif., Sep 05, 2014 (BUSINESS WIRE) -- NovaBay® Pharmaceuticals, Inc. (nyse mkt:NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, today announced that ...
NovaBay Pharmaceuticals Deploys Direct Sales Force to Market i-Lid Cleanser ...
Yahoo Finance UK - Aug 25, 2014
NovaBay Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, announced today that its i-Lid Cleanser sales force has been deployed in 10 ...
NovaBay Pharmaceuticals Sees Significant Decrease in Short Interest (NBY)
Intercooler - Sep 12, 2014
NovaBay Pharmaceuticals, Inc. logo Shares of NovaBay Pharmaceuticals (NYSE:NBY) were the recipient of a significant decrease in short interest during the month of August.
Hot Alert : NovaBay Pharmaceuticals (NYSEMKT:NBY), National Bank of Greece ... - WallStreet Scope
Short Interest in NovaBay Pharmaceuticals Decreases By 75.9% (NBY)
sleekmoney - Sep 11, 2014
NovaBay Pharmaceuticals, Inc. logo NovaBay Pharmaceuticals (NYSE:NBY) was the target of a significant decrease in short interest in August.
Short Interest in Novabay Pharmaceutic Decreases By 75.9% (NBY) - WKRB News
News Buzz: NovaBay Pharmaceuticals (NYSEMKT: NBY), Microsoft Corporation ...
WallStreet Scope - Sep 2, 2014
On 28 AUG NovaBay Pharmaceuticals, Inc. (NYSEMKT: NBY) announced that it has added four new members to its Ophthalmic Advisory Board (OAB), who will join the ten existing members of the board.
Market Movers : Cubist Pharmaceuticals Inc. (NASDAQ:CBST), Honeywell ...
WallStreet Scope - Sep 15, 2014
NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) a bio-pharmaceutical company focussing on the development and commercialisation of its non-antibiotic anti-infective products, and China Pioneer Pharma Holdings, Limited, a leading marketer of branded ...
Today's Hot List: NovaBay Pharmaceuticals, Inc. (NYSEMKT: NBY), Oi SA ...
eFinance Hub - Aug 21, 2014
NovaBay Pharmaceuticals, Inc. (NYSEMKT: NBY) announced that its NVC-422 ophthalmic formulation did not meet the primary or secondary endpoints in a Phase 2 clinical study in patients with adenoviral conjunctivitis.
Mid-Day Buzzers – NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY),Vringo, Inc ... - Techsonian (press release)
Stocks to Track - NovaBay Pharmaceuticals, Inc. (NBY), Dyax Corp. (DYAX ...
Techsonian (press release) - Aug 25, 2014
Birmingham, West Midlands - (TechSonian) - 25 August 2014 - NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY)released that its NVC-422 ophthalmic formulation did not meet the primary or secondary endpoints in a Phase 2 clinical study in patients with ...
Today's Watch List: Bio-Path Holdings (NASDAQ:BPTH), NovaBay ... - WallStreet Scope